目的 探討西黃丸聯(lián)合貝伐珠單抗注射液治療晚期結(jié)直腸癌的治療效果。方法 選取2021年8月—2023年8月保定市第一醫(yī)院收治的晚期結(jié)直腸癌患者86例，參照隨機(jī)數(shù)字表法分為對照組（43例）和治療組（43例）。對照組患者靜脈滴注貝伐珠單抗注射液，5 mg/(kg?d)，持續(xù)時(shí)間90 min以上，1次/2周。治療組患者在對照組的基礎(chǔ)上口服西黃丸，3 g/次，2次/d。兩組均治療8周。比較兩組的臨床療效、Karnofsky（KPS）評分、生活質(zhì)量（QOL）評分和血清腫瘤標(biāo)志物水平。結(jié)果 相較于對照組，治療組患者的客觀緩解率、疾病控制率較高（P＜0.05）。治療后，兩組的KPS、QOL評分均顯著升高（P＜0.05），且治療組KPS、QOL評分明顯高于對照組（P＜0.05）。治療后，兩組血清糖類抗原19-9（CA19-9）、糖類抗原125（CA125）、癌胚抗原（CEA）、糖類抗原242（CA242）水平均顯著降低（P＜0.05），且治療組血清腫瘤標(biāo)志物水平均顯著低于對照組（P＜0.05）。結(jié)論 西黃丸聯(lián)合貝伐珠單抗注射液治療晚期結(jié)直腸癌療效確切，可改善患者生存質(zhì)量，降低腫瘤標(biāo)志物水平。

Objective To explore the therapeutic effect of Xihuang Pills combined with Bevacizumab Injection in treatment of advanced colorectal cancer. Methods Patients (86 cases) with advanced colorectal cancer in Baoding NO. 1 Hospital from August 2021 to August 2023 were divided into control and treatment groups according to the random number table method, and each group had 43 cases. Patients in the control group were iv administered with Bevacizumab Injection, 5 mg/(kg?d), infusion duration of more than 90 min, once per two weeks. Patients in the treatment group were po administered with Xihuang Pills on the basis of the control group, 3 g/time, twice daily. Patients in two groups were treated for 8 weeks. The clinical efficacies, QOL scores, KPS scores, and serum tumor marker levels in two groups were compared. Results Compared with the control group, ORR and CBR of the treatment group were higher (P < 0.05). After treatment, KPS scores and QOL scores in two groups were significantly increased (P < 0.05), and KPS scores and QOL scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the serum levels of CA19-9, CA125, CEA, and CA242 in two groups were significantly decreased (P < 0.05), and the serum tumor marker levels in treatment group were significantly lower than those in control group (P < 0.05). Conclusion Xihuang Pills combined with Bevacizumab Injection is effective in treatment of advanced colorectal cancer, can improve the quality of life of patients, reduce the level of tumor markers.

R979.1

保定市科技計(jì)劃項(xiàng)目（2241ZF034）